Literature DB >> 22649158

Evaluation of monoclonal antibody-based immunohistochemistry for the detection of European and North American Porcine reproductive and respiratory syndrome virus and a comparison with in situ hybridization and reverse transcription polymerase chain reaction.

Kiwon Han1, Hwi Won Seo, Yeonsu Oh, Ikjae Kang, Changhoon Park, Sang Hoon Kang, Sung-Hoon Kim, Bog-Hieu Lee, Byungjoon Kwon, Chanhee Chae.   

Abstract

The objective of the present study was to compare the ability of 2 monoclonal antibodies (mAbs; SDOW17 and SR30) to detect types 1 and 2 Porcine reproductive and respiratory syndrome virus (PRRSV) in formalin-fixed, paraffin-embedded (FFPE) lung tissues by immunohistochemistry (IHC) and to compare the immunohistochemical results with in situ hybridization (ISH) and reverse transcription nested polymerase chain reaction (RT-nPCR) detection techniques. Lungs from 30 experimentally infected pigs (15 pigs with each genotype of PRRSV) and 20 naturally infected pigs (10 pigs with each genotype of PRRSV) with types 1 and 2 PRRSV, respectively, were used for the IHC, ISH, and RT-nPCR analyses. The SR30 mAb-based IHC detected significantly more type 1 PRRSV-positive cells in the accessory and caudal lobes from the experimentally infected pigs at 7 (P = 0.025) and 14 (P = 0.018) days postinoculation, respectively, compared to the SDOW17 mAb-based IHC. The results demonstrated that SR30 mAb-based IHC is useful for detecting both types 1 and 2 PRRSV antigen in FFPE lung tissues.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22649158     DOI: 10.1177/1040638712446507

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  7 in total

1.  Comparison of 2 commercial single-dose Mycoplasma hyopneumoniae vaccines and porcine reproductive and respiratory syndrome virus (PRRSV) vaccines on pigs dually infected with M. hyopneumoniae and PRRSV.

Authors:  Changhoon Park; Ikjae Kang; Hwi Won Seo; Jiwoon Jeong; Kyuhyung Choi; Chanhee Chae
Journal:  Can J Vet Res       Date:  2016-04       Impact factor: 1.310

2.  A new modified live porcine reproductive and respiratory syndrome vaccine improves growth performance in pigs under field conditions.

Authors:  Changhoon Park; Hwi Won Seo; Ikjae Kang; Jiwoon Jeong; Kyuhyung Choi; Chanhee Chae
Journal:  Clin Vaccine Immunol       Date:  2014-07-23

3.  Comparison of 3 vaccination strategies against porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae, and porcine circovirus type 2 on a 3 pathogen challenge model.

Authors:  Jiwoon Jeong; Ikjae Kang; Seeun Kim; Kee Hwan Park; Changhoon Park; Chanhee Chae
Journal:  Can J Vet Res       Date:  2018-01       Impact factor: 1.310

4.  Comparative effects of vaccination against porcine circovirus type 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) in a PCV2-PRRSV challenge model.

Authors:  Changhoon Park; Yeonsu Oh; Hwi Won Seo; Kiwon Han; Chanhee Chae
Journal:  Clin Vaccine Immunol       Date:  2013-01-09

5.  Comparative evaluation of the efficacy of commercial and prototype PRRS subunit vaccines against an HP-PRRSV challenge.

Authors:  Do Tien Duy; Hanjin Kim; Jiwoon Jeong; Kee Hwan Park; Siyeon Yang; Taehwan Oh; Seeun Kim; Ikjae Kang; Chanhee Chae
Journal:  J Vet Med Sci       Date:  2018-07-18       Impact factor: 1.267

6.  Development of luciferase-linked antibody capture assay based on luciferase immunoprecipitation systems for antibody detection of porcine reproductive and respiratory syndrome virus.

Authors:  Jie Li; Gang Wang; Di Yang; Bao Zhao; Yongpan Zhao; Yonggang Liu; Xuehui Cai; Yuchen Nan; En-Min Zhou; Chunyan Wu
Journal:  BMC Biotechnol       Date:  2018-11-16       Impact factor: 2.563

7.  Comparative pathogenesis of type 1 (European genotype) and type 2 (North American genotype) porcine reproductive and respiratory syndrome virus in infected boar.

Authors:  Kiwon Han; Hwi Won Seo; Changhoon Park; Yeonsu Oh; Ikjae Kang; Chanhee Chae
Journal:  Virol J       Date:  2013-05-21       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.